

DOCKET NO: ISIS0124-100 (RTS-0739US)

PATENT

**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 9, 14, 17-20, 22, 23, 26, 27, 29, and 30 without prejudice to their presentation in another application, and amend claims 1, 13, 24 and 25 as follows.

1. (currently amended) An antisense compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding ACE2 (SEQ ID NO:4), wherein said compound is ~~at least 70% at least 85%~~ complementary to said nucleic acid molecule encoding ACE2 (SEQ ID NO:4), ~~wherein said compound comprises at least one 2'-O-methoxyethyl sugar moiety and wherein said compound inhibits the expression of ACE2 mRNA by at least 10%.~~
2. (original) The antisense compound of claim 1 comprising 12 to 50 nucleobases in length.
3. (original) The antisense compound of claim 2 comprising 15 to 30 nucleobases in length.
4. (original) The antisense compound of claim 1 comprising an oligonucleotide.
5. (original) The antisense compound of claim 4 comprising a DNA oligonucleotide.
6. (original) The antisense compound of claim 4 comprising an RNA oligonucleotide.
7. (original) The antisense compound of claim 4 comprising a chimeric oligonucleotide.
8. (original) The antisense compound of claim 4 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.
9. (cancelled).

DOCKET NO: ISIS0124-100 (RTS-0739US)

PATENT

10. (original) The antisense compound of claim 1 having at least 90% complementarity with said nucleic acid molecule encoding ACE2.
11. (original) The antisense compound of claim 1 having at least 95% complementarity with said nucleic acid molecule encoding ACE2.
12. (original) The antisense compound of claim 1 having at least 99% complementarity with said nucleic acid molecule encoding ACE2.
13. (currently amended) The antisense compound of claim 1 having at least one modified internucleoside linkage, ~~sugar moiety~~, or nucleobase.
14. (cancelled).
15. (original) The antisense compound of claim 1 having at least one phosphorothioate internucleoside linkage.
16. (original) The antisense compound of claim 1 wherein at least one cytosine is a 5-methylcytosine.
- 17-20. (cancelled).
21. (original) A kit or assay device comprising the antisense compound of claim 1.
- 22-23. (cancelled).
24. (currently amended) The antisense compound of claim 1, wherein said antisense compound comprises at least an 8-nucleobase portion of SEQ ID NOs ~~NOs~~ 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 26, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 40, 42, 43, 45, 46, 49, 50, 51, 52, 53, 55,

**DOCKET NO: ISIS0124-100 (RTS-0739US)**

**PATENT**

56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 76, 77, 78, 80, 82, 86, 88, 89 or 90.

25. (currently amended) The antisense compound of claim 24, wherein said antisense compound has a sequence selected from the group consisting of SEQ ID NOs ~~NOs~~ 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 26, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 40, 42, 43, 45, 46, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 76, 77, 78, 80, 82, 86, 88, 89 and 90.

26-27. (cancelled).

28. (original) The antisense compound of claim 1, wherein said antisense compound comprises an antisense nucleic acid molecule that is specifically hybridizable with a coding region of a nucleic acid molecule encoding ACE2.

29-30. (cancelled).